AAPL vs ABT Stock Comparison

Scores Breakdown

Metric	AAPL	ABT
📈 Growth	22/30	18/30
💰 Profitability	14/20	17/20
🏦 Financial Health	18/20	18/20
💵 Valuation	15/20	12/20
⚠️ Risk (lower is better)	6/10	4/10
Overall Score	73/100	71/100

Side-by-Side Summaries

AAPL Analysis	ABT Analysis
📈 Growth & Financial Trajectory Over 8 quarters Apple progressed from Revenues of $94.93B in 2024Q4 to $109.42B in 2026Q3, with a notable mid-period spike to $143.76B in 2025Q3. Net income rose from $14.74B to $29.79B, signaling solid earnings growth despite volatility in quarterly mix. The sequence ends with higher absolute revenue and sustained profitability versus the start, though the pace is uneven. 💰 Margins & Cash Flow Gross margin fluctuated: early quarters near the 60%+ range, dipping to the mid-40s–50s during 2025Q3, then stabilizing around the low- to mid-50% range in 2026. Operating margin followed suit, with positive cash flow from operations in most quarters and generally positive free cash flow despite variable investing cash flow. Net cash from operating activities remained positive across the window; financing cash flows were typically negative. 🛡️ Balance Sheet & Liquidity Assets stay robust at roughly $330B–$379B, with liabilities around $264B–$291B and equity in the $56B–$88B range, indicating a solid balance sheet. Current assets exceed current liabilities in most periods, supporting liquidity, while long-term debt remains modest relative to earnings power. ⚠️ Key Drivers & Risks Drivers: iPhone and Services acceleration; broad ecosystem and high-margin software/services expansion. Risks: demand cyclicality and competitive/margin pressure; regulatory/valuation sensitivity to hardware cycles.	📈 Growth & Financial Trajectory Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B. 💰 Margins & Cash Flow Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter. Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B). 🛡️ Balance Sheet & Liquidity Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow. ⚠️ Key Drivers & Risks Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management. Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.

AAPL Analysis

ABT Analysis

📈 Growth & Financial Trajectory

Over 8 quarters Apple progressed from Revenues of $94.93B in 2024Q4 to $109.42B in 2026Q3, with a notable mid-period spike to $143.76B in 2025Q3. Net income rose from $14.74B to $29.79B, signaling solid earnings growth despite volatility in quarterly mix. The sequence ends with higher absolute revenue and sustained profitability versus the start, though the pace is uneven.

💰 Margins & Cash Flow

Gross margin fluctuated: early quarters near the 60%+ range, dipping to the mid-40s–50s during 2025Q3, then stabilizing around the low- to mid-50% range in 2026. Operating margin followed suit, with positive cash flow from operations in most quarters and generally positive free cash flow despite variable investing cash flow. Net cash from operating activities remained positive across the window; financing cash flows were typically negative.

🛡️ Balance Sheet & Liquidity

Assets stay robust at roughly $330B–$379B, with liabilities around $264B–$291B and equity in the $56B–$88B range, indicating a solid balance sheet. Current assets exceed current liabilities in most periods, supporting liquidity, while long-term debt remains modest relative to earnings power.

⚠️ Key Drivers & Risks

Drivers: iPhone and Services acceleration; broad ecosystem and high-margin software/services expansion.
Risks: demand cyclicality and competitive/margin pressure; regulatory/valuation sensitivity to hardware cycles.

📈 Growth & Financial Trajectory

Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B.

💰 Margins & Cash Flow

Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter.
Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B).

🛡️ Balance Sheet & Liquidity

Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow.

⚠️ Key Drivers & Risks

Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management.
Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.

Similar Companies

AMZN Score: 80 BRK.B Score: 60 DIS Score: 76 GOOG Score: 80 GOOGL Score: 80 META Score: 76 MSFT Score: 86 NFLX Score: 75 NVDA Score: 78 TSLA Score: 64

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"